Price Alert

Johnson & Johnson (JNJ)

NYSE: JNJ · Real-Time Price · USD

190.80

-0.10 (-0.05%)

At close: Oct 14, 2025, 3:59 PM

191.10

0.16%

After-hours: Oct 14, 2025, 07:59 PM EDT

-0.05% (1D)

Bid	190
Market Cap	459.51B
Revenue (ttm)	90.63B
Net Income (ttm)	22.66B
EPS (ttm)	9.34
PE Ratio (ttm)	20.43
Forward PE	16.74
Analyst	Buy
Dividends	$6.32

Ask	191
Volume	11,272,499
Avg. Volume (20D)	8,666,342
Open	192.92
Previous Close	190.90
Day's Range	185.97 - 194.39
52-Week Range	140.68 - 194.39
Beta	0.39
Ex-Dividend Date	Aug 26, 2025

About JNJ

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol JNJ

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for JNJ stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Johnson & Johnson has released their quartely earnings on Oct 14, 2025:

Revenue of $23.99B exceeds estimates by $243.78M, with 6.77% YoY growth.

EPS of 2.8 exceeds estimates by 0.04, with 15.70% YoY growth.

Next Earnings Release

Johnson & Johnson is scheduled to release its earnings on Jan 21, 2026, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

19 hours ago New

-0.03%

JNJ stock has given up its prior gain. Johnson & J... Unlock content with Pro Subscription

21 hours ago New

-0.03%

Johnson & Johnson shares are trading higher after the company reported Q3 adjusted EPS and sales above estimates and raised its FY2025 sales guidance.

News

14 hours ago · youtube.com

'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations

Johnson & Johnson CFO and Executive Vice President Joe Wolk addresses the decision to spin off its orthopedics business, explains its innovations and more on ‘The Claman Countdown.' #fox #media #break...

20 hours ago · zacks.com

JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit

J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.

20 hours ago · zacks.com

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

20 hours ago · seekingalpha.com

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Johnson & Johnson (NYSE:JNJ ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wol...

22 hours ago · 247wallst.com

3 Dividend Aristocrats to Buy that Continued to Beat the Market

Finding top dividend stocks to invest in is one thing. Finding companies that can pay that dividend for years, and potentially decades, to come is a whole other story.

23 hours ago · zacks.com

Compared to Estimates, Johnson & Johnson (JNJ) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with...

23 hours ago · schaeffersresearch.com

Johnson & Johnson Stock Brushes Off Beat-and-Raise

Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter.

23 hours ago · youtube.com

Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides

While big banks as a group posted strong earnings, Diane King Hall notes Citigroup (C) as a standout. She talks about how stronger IPO and dealmaking markets added muscle for the company.

23 hours ago · proactiveinvestors.com

Johnson & Johnson reports Q3 beat, plans orthopaedics spin-off

Johnson & Johnson (NYSE:JNJ) posted third-quarter revenue and earnings that beat Wall Street estimates, driven by strength in its pharmaceuticals and medical devices businesses. The healthcare giant r...

1 day ago · seekingalpha.com

Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again

Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 millio...

Load More News